Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Cited by (1,026)

Items 101–200 of 1,026

1. Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.
   Lastwika, Kristin J., Wilson, Willie, Li, Qing Kay, Norris, Jeffrey, Xu, Haiying, Ghazarian, Sharon R., Kitagawa, Hiroshi, Kawabata, Shigeru, Taube, Janis M., Yao, Sheng et al. · 2016 · Cancer Research
2. Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
   Sofía Lyford-Pike, Shiwen Peng, Geoffrey D. Young, Janis Marie Taube, William H. Westra, Belinda Akpeng, Tullia Carmela Bruno, Jeremy D. Richmon, Hao Wang, Justin A. Bishop et al. · 2013 · Cancer Research
3. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
   Thompson, R. Houston, Gillett, Michael D., Cheville, John C., Lohse, Christine M., Dong, Haidong, Webster, W. Scott, Krejci, Kent G., Lobo, John R., Sengupta, Shomik, Chen, Lieping et al. · 2004 · Proceedings of the National Academy of Sciences
4. PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells
   Blank, Christian, Brown, Ian, Peterson, Amy C., Spiotto, Mike, Iwai, Yoshiko, Honjo, Tasuku, Gajewski, Thomas F. · 2004 · Cancer Research
5. CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
   Deng, Jiehui, Wang, Eric S., Jenkins, Russell W., Li, Shuai, Dries, Ruben, Yates, Kathleen, Chhabra, Sandeep, Huang, Wei, Liu, Hongye, Aref, Amir R. et al. · 2018 · Cancer Discovery
6. Modulation of the antitumor immune response by complement
   Maciej M. Markiewski, Robert A. DeAngelis, Fabián Benencia, Salome K. Ricklin-Lichtsteiner, Anna Koutoulaki, Craig J Gerard, George Coukos, John D. Lambris · 2008 · Nature Immunology
7. Targeting FTO suppresses cancer stem cell maintenance and immune evasion
   R. Su, Lei Dong, Yang-Chan Li, Min Gao, Li Han, M. Wunderlich, Xiaolan Deng, Hongzhi Li, Yue Huang, Lei Gao et al. · 2020 · Cancer Cell
8. Tumor biomarkers for diagnosis, prognosis and targeted therapy
   Yue Zhou, Lei Tao, Jiahao Qiu, Jing Xu, Xinyu Yang, Yu Zhang, Xinyu Tian, Xinqi Guan, Xiaobo Cen, Yinglan Zhao · 2024 · Signal Transduction and Targeted Therapy
9. Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
   Highfill, Steven L., Cui, Yongzhi, Giles, Amber J., Smith, Jillian P., Zhang, Hua, Morse, Elizabeth, Kaplan, Rosandra N., Mackall, Crystal L. · 2014 · Science Translational Medicine
10. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells
    Barsoum, Ivraym B., Smallwood, Chelsea A., Siemens, D. Robert, Graham, Charles H. · 2014 · Cancer Research
11. The head and neck cancer immune landscape and its immunotherapeutic implications
    Rajarsi Mandal, Yasin Şenbabaoğlu, Alexis Desrichard, Jonathan J. Havel, Martin G. Dalin, Nadeem Riaz, Ken-Wing Lee, Ian Ganly, A. Ari Hakimi, Timothy An-thy Chan et al. · 2016 · JCI Insight
12. Programmed death ligand-1 expression in non-small cell lung cancer
    Vamsidhar Velcheti, Kurt Alex Schalper, Daniel E Carvajal, Valsamo Anagnostou, Konstantinos Nikolaos Syrigos, Mario Sznol, Roy S. Herbst, Scott N. Gettinger, Lieping Chen, David L. Rimm · 2013 · Laboratory Investigation
13. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma
    Kryczek, Ilona, Zou, Linhua, Rodriguez, Paulo, Zhu, Gefeng, Wei, Shuang, Mottram, Peter, Brumlik, Michael, Cheng, Pui, Curiel, Tyler, Myers, Leann et al. · 2006 · The Journal of Experimental Medicine
14. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
    Luc Yves Dirix, István Takács, Guy Jérusalem, Petros G. Nikolinakos, Hendrik‐Tobias Arkenau, Andres Forero, Ralph Vincent Boccia, Marc E. Lippman, Robert A. Somer, Martin Šmakal et al. · 2017 · Breast Cancer Research and Treatment
15. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
    Akintunde Akinleye, Zoaib Rasool · 2019 · Journal of Hematology & Oncology
16. Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
    Jaikumar Duraiswamy, Karen M. Kaluza, Gordon James Freeman, George Coukos · 2013 · Cancer Research
17. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
    Frank Stephen Hodi, Wen‐Jen Hwu, Richard F. Kefford, Jeffrey S. Weber, ADIL I. DAUD, Omid Hamid, Amita Patnaik, Antoni Ribas, Caroline Robert, Tara C. Gangadhar et al. · 2016 · Journal of Clinical Oncology
18. Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
    Wing, James B., Tanaka, Atsushi, Sakaguchi, Shimon · 2019 · Immunity
19. The PD-1–PD-L pathway in immunological tolerance
    Taku Okazaki, Tasuku Honjo · 2006 · Trends in Immunology
20. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
    Li Lily Wang, Rotem Rubinstein, Janet Louise Lines, Anna Wasiuk, Cory L. Ahonen, Yanxia Guo, Li‐Fan Lu, David C. Gondek, Yan Wang, Roy A. Fava et al. · 2011 · The Journal of Experimental Medicine
21. B7-H4, a Molecule of the B7 Family, Negatively Regulates T Cell Immunity
    Gabriel Sica, In-Hak Choi, Gefeng Zhu, Koji Tamada, Sheng-Dian Wang, Hideto Tamura, Andrei I. Chapoval, Dallas B. Flies, Jürgen Bajorath, Lieping Chen · 2003 · Immunity
22. Vaccines for established cancer: overcoming the challenges posed by immune evasion
    Sjoerd H. van der Burg, Ramon Arens, FERRY A. OSSENDORP, Thorbald van Hall, Cornelis J.M. Melief · 2016 · Nature reviews. Cancer
23. Neoantigen vaccine: an emerging tumor immunotherapy
    Peng Miao, Yongzhen Mo, Yian Wang, Pan Wu, Yijie Zhang, Fang Xiong, Can Jie Guo, Steven Wu, Yong Li, Xiaoling Li et al. · 2019 · Molecular Cancer
24. Mechanisms of Immune Evasion by Tumors
    Charles G. Drake, Elizabeth M. Jaffee, Drew M. Pardoll · 2006 · Advances in immunology
25. CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
    Patrick Alexander Ott, Frank Stephen Hodi, Caroline Robert · 2013 · Clinical Cancer Research
26. Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies.
    Byun, David J., Wolchok, Jedd D., Rosenberg, Lynne M., Girotra, Monica · 2017 · Nature Reviews Endocrinology
27. Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
    Raanan Berger, Rinat Rotem‐Yehudar, Gideon Slama, Shimon Landes, Abraham Kneller, Merav Leiba, Maya Koren‐Michowitz, Avichai Shimoni, Arnon Nagler · 2008 · Clinical Cancer Research
28. B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression
    Jun Sakakibara Konishi, Koichi Yamazaki, Miyuki Azuma, Ichiro Kinoshita, Hirotoshi Dosaka‐Akita, Masaharu Nishimura · 2004 · Clinical Cancer Research
29. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
    Jun Wang, Jingwei Sun, Linda N. Liu, Dallas B. Flies, Xinxin Nie, Maria I Toki, Jianping Zhang, Chang Cheng Song, Melissa A. Zarr, Xu Zhou et al. · 2019 · Nature Medicine
30. Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma
    Ryosuke Hino, Kenji Kabashima, Yu Kato, Hiroaki Yagi, Motonobu Nakamura, Tasuku Honjo, Taku Okazaki, YOSHIKI TOKURA · 2010 · Cancer
31. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
    Kabir A. Khan, Robert S. Kerbel · 2018 · Nature Reviews Clinical Oncology
32. CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions
    Masao Hashimoto, Alice Oliffson Kamphorst, Se Jin Im, Haydn Thomas Kissick, Rathi Narayana Pillai, Suresh S. Ramalingam, Koichi Araki, Rafi Ahmed · 2018 · Annual Review of Medicine
33. HUMAN T CELL RESPONSES AGAINST MELANOMA
    Thierry Boon, Pierre G. Coulie, Benoit J. Van den Eynde, Pierre van der Bruggen · 2005 · Annual Review of Immunology
34. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
    Kim, J.M., Chen, D.S. · 2016 · Annals of Oncology
35. Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
    Daniel S. Chen, Bryan A. Irving, Frank Stephen Hodi · 2012 · Clinical Cancer Research
36. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
    Sonja Kleffel, Christian Posch, Steven R. Barthel, Hansgeorg Mueller, Christoph Schlapbach, Emmanuella Guenova, Christopher P. Elco, Nayoung Lee, Vikram R. Juneja, Qian Zhan et al. · 2015 · Cell
37. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
    Charlene Marie Fares, Eliezer M. Van Allen, Charles G. Drake, James Patrick Allison, Siwen Hu‐Lieskovan · 2019 · American Society of Clinical Oncology Educational Book
38. Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses
    Spencer C. Liang, Yvette E Latchman, Janet E. Buhlmann, Michal F. Tomczak, Bruce Harold Horwitz, Gordon James Freeman, Arlene H. Sharpe · 2003 · European Journal of Immunology
39. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy
    Christian U. Blank, Thomas Frank Gajewski, Andréas Mackensen · 2004 · Cancer Immunology Immunotherapy
40. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells
    Yvette E Latchman, Spencer C. Liang, Yin Wu, Tatyana Chernova, Raymond A. Sobel, Martina Klemm, Vijay Kumar Kuchroo, Gordon James Freeman, Arlene H. Sharpe · 2004 · Proceedings of the National Academy of Sciences
41. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells
    P’ng Loke, James Patrick Allison · 2003 · Proceedings of the National Academy of Sciences
42. Immunostimulatory monoclonal antibodies for cancer therapy
    Ignacio Melero, Sandra Hervás‐Stubbs, Martin J. Glennie, Drew M. Pardoll, Lieping Chen · 2007 · Nature reviews. Cancer
43. Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients
    Theodoraki, Marie-Nicole, Yerneni, Saigopalakrishna S., Hoffmann, Thomas K., Gooding, William E., Whiteside, Theresa L. · 2018 · Clinical Cancer Research
44. CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients
    Djenidi, Fayçal, Adam, Julien, Goubar, Aïcha, Durgeau, Aurélie, Meurice, Guillaume, de Montpréville, Vincent, Validire, Pierre, Besse, Benjamin, Mami-Chouaib, Fathia · 2015 · The Journal of Immunology
45. Clinical blockade of PD1 and LAG3 — potential mechanisms of action
    Linh T. Nguyen, Pamela S. Ohashi · 2014 · Nature reviews. Immunology
46. Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity
    Elise Alspach, Danielle M. Lussier, Robert D. Schreiber · 2018 · Cold Spring Harbor Perspectives in Biology
47. Prostate cancer and inflammation: the evidence
    Karen Sandell Sfanos, Angelo Michael De Marzo · 2011 · Histopathology
48. The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic Factors
    Hazem Ghebeh, Shamayel F. Mohammed, Abeer Al-Omair, Amal T. Qattan, Cynthia L. Lehé, Ghofran Al-Qudaihi, Naser B. Elkum, Mohamed Alshabanah, Suad M. Bin Amer, Asma M. Tulbah et al. · 2006 · Neoplasia
49. Emerging Concepts in the Immunopathogenesis of AIDS
    Daniel C. Douek, Mario Roederer, Richard A. Koup · 2008 · Annual Review of Medicine
50. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
    Chia‐Wei Li, Seung‐Oe Lim, Ezra M. Chung, Yongsoo Kim, Andrew H Park, Jun Yao, Jong‐Ho Cha, Weiya Xia, Li-Chuan Chan, Tae‐Wan Kim et al. · 2018 · Cancer Cell
51. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
    Bardhan, Kankana, Anagnostou, Theodora, Boussiotis, Vassiliki A. · 2016 · Frontiers in Immunology
52. In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
    Changyu Wang, Kent B. Thudium, Minhua Han, Xitao Wang, Haichun Huang, Diane Feingersh, Candy Garcia, Yi Ming Wu, Michelle R. Kuhné, Mohan Srinivasan et al. · 2014 · Cancer Immunology Research
53. Deciphering and Reversing Tumor Immune Suppression
    Gregory T. Motz, George Coukos · 2013 · Immunity
54. Cancer stem cells: advances in knowledge and implications for cancer therapy
    Xianjing Chu, Wentao Tian, Jiaoyang Ning, Gang Xiao, Yunqi Zhou, Ziqi Wang, Zhuofan Zhai, Guilong Tanzhu, Jie Yang, Rongrong Zhou · 2024 · Signal Transduction and Targeted Therapy
55. Cancer Immunotherapy Comes of Age
    Suzanne Louise Topalian, George J. Weiner, Drew M. Pardoll · 2011 · Journal of Clinical Oncology
56. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway
    Jizhong Liu, Abdelbasset Hamrouni, Dariusz Wołowiec, Valérie Coiteux, Kazimierz Kuliczkowski, Dominique Hétuin, Aurore Saudemont, Bruno Quesnel · 2007 · Blood
57. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
    Heng Lin, Shuang Wei, Elaine M. Hurt, Michael D. Green, Lili Zhao, Linda Vatan, Wojciech Szeliga, Ronald Herbst, Paul W. Harms, Leslie Anne Fecher et al. · 2018 · Journal of Clinical Investigation
58. Checkpoint Blockade in Cancer Immunotherapy
    Alan J. Korman, Karl S. Peggs, James Patrick Allison · 2006 · Advances in immunology
59. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
    Chuanyong Mu, Jian‐An Huang, Ying Chen, Cheng Chen, Xueguang Zhang · 2010 · Medical Oncology
60. The B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responses
    Suh, Woong-Kyung, Gajewska, Beata U, Okada, Hitoshi, Gronski, Matthew A, Bertram, Edward M, Dawicki, Wojciech, Duncan, Gordon S, Bukczynski, Jacob, Plyte, Suzanne, Elia, Andrew et al. · 2003 · Nature Immunology
61. Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment
    Zhenyu Zhong, Elsa Sánchez‐López, Michael Karin · 2016 · Cell
62. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
    Siwen Hu‐Lieskovan, Stephen Mok, Blanca Homet Moreno, Jennifer Tsoi, Lídia Robert, Lucas Goedert, Elaine M. Pinheiro, Richard Chikara Koya, Thomas G. Graeber, Begoña Comı́n-Anduix et al. · 2015 · Science Translational Medicine
63. Improving immune–vascular crosstalk for cancer immunotherapy
    Huang, Yuhui, Kim, Betty Y. S., Chan, Charles K., Hahn, Stephen M., Weissman, Irving L., Jiang, Wen · 2018 · Nature Reviews Immunology
64. PD-1/PD-L1 inhibitors
    Joel Chaim Sunshine, Janis Marie Taube · 2015 · Current Opinion in Pharmacology
65. The foundations of immune checkpoint blockade and the ipilimumab approval decennial
    Alan J. Korman, Sarah C. Garrett-Thomson, Nils Lönberg · 2021 · Nature Reviews Drug Discovery
66. DNA mismatch repair in cancer
    Marina Baretti, Dung Thi Le · 2018 · Pharmacology & Therapeutics
67. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
    Simone E. Muenst, A. R. Schaerli, Feng Gao, Silvio Däster, Emanuele Trella, Raoul Andre Droeser, Manuele Giuseppe Muraro, Paul Zajac, Rosanna Zanetti, William E. Gillanders et al. · 2014 · Breast Cancer Research and Treatment
68. Immune-mediated antitumor effect by type 2 diabetes drug, metformin
    Shingo Eikawa, Mikako Nishida, Shusaku Mizukami, Chihiro Yamazaki, Eiichi Nakayama, Heiichiro Udono · 2015 · Proceedings of the National Academy of Sciences
69. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
    Spranger, Stefani, Koblish, Holly K, Horton, Brendan, Scherle, Peggy A, Newton, Robert, Gajewski, Thomas F · 2014 · Journal for ImmunoTherapy of Cancer
70. Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
    Li, Qing, Geng, Shan, Luo, Hao, Wang, Wei, Mo, Ya-Qi, Luo, Qing, Wang, Lu, Song, Guan-Bin, Sheng, Jian-Peng, Xu, Bo · 2024 · Signal Transduction and Targeted Therapy
71. Erratum: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
    Haidong Dong, Scott Eric Strome, Diva R. Salomão, Hideto Tamura, Fumiya Hirano, Dallas B. Flies, Patrick C. Roche, Jun Lu, Gefeng Zhu, Koji Tamada et al. · 2002 · Nature Medicine
72. Toll-Like Receptors on Tumor Cells Facilitate Evasion of Immune Surveillance
    Bo Huang, Jie Zhao, Hongxing Li, Kai‐Li He, Yibang Chen, Lloyd F. Mayer, Jay C. Unkeless, Huabao Xiong · 2005 · Cancer Research
73. Tumor Immunology and Tumor Evolution: Intertwined Histories
    Jérôme Galon, Daniela Bruni · 2020 · Immunity
74. Revisiting the PD-1 pathway
    Nikolaos Patsoukis, Qi Wang, Laura Strauss, Vassiliki A. Boussiotis · 2020 · Science Advances
75. Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
    Frank Alexander Schildberg, Sarah R. Klein, Gordon James Freeman, Arlene H. Sharpe · 2016 · Immunity
76. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
    Jean‐Sébastien Frenel, Christophe Le Tourneau, Bert H. O’Neil, Patrick Alexander Ott, Sarina Anne Piha-Paul, Carlos Gomez‐Roca, Emilie M.J. van Brummelen, Hope S. Rugo, Shari Thomas, Sanatan Saraf et al. · 2017 · Journal of Clinical Oncology
77. Tumour immunity: effector response to tumour and role of the microenvironment
    Alberto Mantovani, Pedro J. Romero, Anna Karolina Palucka, Francesco Maria Marincola · 2008 · The Lancet
78. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma
    Weber, Jeffrey S., Kudchadkar, Ragini Reiney, Yu, Bin, Gallenstein, Donna, Horak, Christine E., Inzunza, H. David, Zhao, Xiuhua, Martinez, Alberto J., Wang, Wenshi, Gibney, Geoffrey et al. · 2013 · Journal of Clinical Oncology
79. Updates on global epidemiology, risk and prognostic factors of gastric cancer
    Wenjuan Yang, Heping Zhao, Yan Ping Yu, Ji-Han Wang, Lei Guo, Jun-Ye Liu, Jie Pu, Jing Lv · 2023 · World Journal of Gastroenterology
80. Targeting tumours with genetically enhanced T lymphocytes
    Michel Sadelain, Isabelle Rivière, Renier J. Brentjens · 2003 · Nature reviews. Cancer
81. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond
    Luoyan Ai, Antao Xu, Jie Xu · 2020 · Advances in experimental medicine and biology
82. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection
    Natalia Rubinstein, Mariano J. Alvarez, Norberto W. Zwirner, Marta A. Toscano, Juan M. Ilarregui, Alicia Bravo, José Mordoh, Leonardo Fainboim, Osvaldo Luis Podhajcer, Gabriel A. Rabinovich · 2004 · Cancer Cell
83. Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response
    Mario Sznol, Lieping Chen · 2013 · Clinical Cancer Research
84. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
    Takeshi Azuma, Sheng Yao, Gefeng Zhu, Andrew S. Flies, Sarah J. Flies, Lieping Chen · 2008 · Blood
85. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells
    Iwai, Y. · 2004 · International Immunology
86. Application of PD-1 Blockade in Cancer Immunotherapy
    Xiaomo Wu, Zhongkai Gu, Chen Yang, Borui Chen, Wei Chen, Liqiang Weng, Xiaolong Liu · 2019 · Computational and Structural Biotechnology Journal
87. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
    Dongrui Wang, Xianlin Wu, Yingli Sun · 2022 · Signal Transduction and Targeted Therapy
88. Immune Modulation in Cancer with Antibodies
    David B. Page, Michael A. Postow, Margaret K. Callahan, James Patrick Allison, Jedd D. Wolchok · 2013 · Annual Review of Medicine
89. The Common γ-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands
    Kinter, Audrey L., Godbout, Emily J., McNally, Jonathan P., Sereti, Irini, Roby, Gregg A., O’Shea, Marie A., Fauci, Anthony S. · 2008 · The Journal of Immunology
90. Role of the Tumor Microenvironment in Breast Cancer
    Savas Deniz Soysal, Alexandar Tzankov, Simone E. Muenst · 2015 · Pathobiology
91. Pembrolizumab (Keytruda)
    Gin Wai Kwok, Thomas C. C. Yau, Joanne Wing Yan Chiu, Eric Tse, Yok‐Lam Kwong · 2016 · Human Vaccines & Immunotherapeutics
92. 5‐Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes
    Blondy, Sabrina, David, Valentin, Verdier, Mireille, Mathonnet, Muriel, Perraud, Aurélie, Christou, Niki · 2020 · Cancer Science
93. Prognostic and predictive value of PDL1 expression in breast cancer
    Renaud Sabatier, Pascal Finetti, Émilie Mamessier, José Adélaı̈de, Max Chaffanet, Hamid Raza Ali, Patrice Viens, Carlos Caldas, Daniel Birnbaum, François Bertucci · 2014 · Oncotarget
94. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion
    Christian U. Blank, Andréas Mackensen · 2006 · Cancer Immunology Immunotherapy
95. Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune Encephalomyelitis
    Alan David Salama, Tanuja Chitnis, Jaime Imitola, Mohammed Javeed Ansari, Hisaya Akiba, Fumihiko Tushima, Miyuki Azuma, Hideo Yagita∥, Mohamed H. Sayegh, Samia Joseph Khoury · 2003 · The Journal of Experimental Medicine
96. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma
    Li, Hang, Wu, Ke, Tao, Kaixiong, Chen, Libo, Zheng, Qichang, Lu, Xiaoming, Liu, Jun, Shi, Liang, Liu, Chuanqiao, Wang, Guobin et al. · 2012 · Hepatology
97. COX2/mPGES1/PGE ₂ pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells
    Prima, Victor, Kaliberova, Lyudmila N., Kaliberov, Sergey, Curiel, David T., Kusmartsev, Sergei · 2017 · Proceedings of the National Academy of Sciences
98. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance
    Changping Wu, Yibei Zhu, Jingting Jiang, Jiemin Zhao, Xueguang Zhang, Ning Xu · 2006 · Acta Histochemica
99. Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
    Mario Sznol, Lieping Chen · 2013 · Clinical Cancer Research
100. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
     Scott Eric Strome, Haidong Dong, Hideto Tamura, Stephen G. Voss, Dallas B. Flies, Koji Tamada, Diva R. Salomão, John C. Cheville, Fumiya Hirano, Wei Yu Lin et al. · 2003 · PubMed